Brought to you by 
Biogen, UPenn ally in gene therapies for multiple indications
25 Mar 2022
Executive Summary
Under a multi-year agreement potentially worth up to $2bn in research funding, option payments, and milestones, Biogen Inc. and the University of Pennsylvania are teaming up to develop gene therapies and advance gene therapy and gene editing technologies, mostly focused on ophthalmic, musculoskeletal, and neurological diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen, UPenn ally in gene therapies for multiple indications
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice